See more : Niraku GC Holdings, Inc. (1245.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Sera Prognostics, Inc. (SERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sera Prognostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- PolyNovo Limited (PNV.AX) Income Statement Analysis – Financial Results
- The Allstate Corporation (ALL) Income Statement Analysis – Financial Results
- Pt Wicaksana Overseas International Tbk (WICO.JK) Income Statement Analysis – Financial Results
- Siemens Energy AG (SMEGF) Income Statement Analysis – Financial Results
- Kanemitsu Corporation (7208.T) Income Statement Analysis – Financial Results
Sera Prognostics, Inc. (SERA)
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K |
| Cost of Revenue | 210.00K | 193.00K | 37.00K | 11.00K | 18.00K |
| Gross Profit | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K |
| Gross Profit Ratio | 31.37% | 27.99% | 54.88% | 56.00% | 50.00% |
| Research & Development | 15.23M | 14.24M | 11.02M | 7.78M | 9.35M |
| General & Administrative | 16.34M | 16.78M | 14.09M | 6.56M | 4.28M |
| Selling & Marketing | 8.35M | 14.70M | 10.33M | 3.65M | 2.96M |
| SG&A | 24.69M | 31.48M | 24.42M | 10.20M | 7.24M |
| Other Expenses | 0.00 | 1.53M | 1.13M | -80.00K | -17.00K |
| Operating Expenses | 39.92M | 45.73M | 35.44M | 17.99M | 16.58M |
| Cost & Expenses | 40.13M | 45.92M | 35.48M | 18.00M | 16.60M |
| Interest Income | 1.64M | 456.00K | 145.00K | 42.00K | 64.00K |
| Interest Expense | 55.00K | 61.00K | 746.00K | 1.84M | 1.97M |
| Depreciation & Amortization | 900.00K | 1.22M | 659.00K | 895.00K | 946.00K |
| EBITDA | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M |
| EBITDA Ratio | -11,531.70% | -16,464.55% | -41,784.15% | -68,456.00% | -37,786.11% |
| Operating Income | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M |
| Operating Income Ratio | -13,013.40% | -17,034.33% | -43,164.63% | -71,884.00% | -45,997.22% |
| Total Other Income/Expenses | 3.58M | 1.47M | 386.00K | -1.88M | 55.00K |
| Income Before Tax | -36.24M | -44.19M | -35.01M | -19.85M | -16.52M |
| Income Before Tax Ratio | -11,843.79% | -16,487.31% | -42,693.90% | -79,392.00% | -45,891.67% |
| Income Tax Expense | 0.00 | 61.00K | 1.22M | 1.76M | 3.92M |
| Net Income | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
| Net Income Ratio | -11,843.79% | -16,510.07% | -44,180.49% | -86,428.00% | -56,775.00% |
| EPS | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| EPS Diluted | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| Weighted Avg Shares Out | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
| Weighted Avg Shares Out (Dil) | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting
SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results...
Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference
SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will...
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will...
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript
Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann...
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the...
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report...
Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will...
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William...
Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024
SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team...
Source: https://incomestatements.info
Category: Stock Reports